progression free survival when a specific antibody-drug conjugate was added to
standard chemotherapy. However, patients with primary refractory disease did
not show any improvement with the added treatment. This study from the
Department of Hematology at Cancer Center Amsterdam was presented at the
International Society on Hodgkin Lymphoma (ISHL12) meeting in Cologne.
A research team including members of the groups of Prof. Marie José Kersten and Prof. Josée M. Zijlstra investigated the effect of the addition of a novel drug, brentuximab vedotin (BV), a CD30 antibody-drug conjugate, to standard chemotherapy and analyzed individual patient data of 10 single arm phase 2 trials.
First author Julia Driessen: “We ‘simulated’ a randomized controlled trial (RCT) by comparing 2 treatment arms that were matched based on propensity scores. Our analysis shows that BV significantly improves outcome for relapsed patients but not for patients with primary refractory disease.”
The researchers also developed a prognostic model based on patient characteristics for progression free survival and are currently developing a prognostic model based on quantitative PET radiomics features.
“Our research improves clinical decision making and underlines the unmet need for the development of novel therapies for primary refractory patients with Hodgkin lymphoma,” says Julia.
Julia Driessen won the poster award at the International Symposium on Hodgkin Lymphoma (ISHL) 2022 for her contribution to this research.
For more information contact Julia Driessen, or read the poster summary here:
Driessen, J., et al. (2022) P107: Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: a Large Multi-Trial Analysis Based on Individual Patient Data. HemaSphere: 6, p 49. doi: 10.1097/01.HS9.0000890996.84518.13
From left to right: Prof. Josée Zijlstra, Julia Driessen and Prof. Marie José Kersten.
Researchers involved from Amsterdam UMC:
Julia Driessen
Fer de Wit
Marie José Kersten
Josée M. Zijlstra
This article was created for Cancer Center Amsterdam.